Heritas Capital Management

Investor type Private Equity Firm


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 22
Average round size
The average size of a deal this fund participated in
Portfolio companies 13
Rounds per year 0.88
Lead investments 7
Follow on index
How often the fund supports its portfolio startups at next rounds
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Biotechnology
  • Wellness
  • Education
  • Medical

The leading representative office of defined VC is situated in the Singapore. The venture was found in Asia in Singapore.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Heritas Capital Management, startups are often financed by Lim Der Shing, Golden Gate Ventures, 500 Startups. The meaningful sponsors for the fund in investment in the same round are Seeds Capital, Bisk Ventures, Wooshin Venture Investment Corp.. In the next rounds fund is usually obtained by Wooshin Venture Investment Corp., Seeds Capital, Mirae Asset Venture Investment.

The fund has specific favorite in a number of founders of portfolio startups. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight ReUp Education, Pathstream, Alodokter. Among the most successful fund investment fields, there are Education, Consulting.

We also calculated 4 valuable employees in our database.

The fund is generally included in 2-6 deals every year. The high activity for fund was in 2019. The real fund results show that this VC is 40 percentage points more often commits exit comparing to other companies. The common things for fund are deals in the range of 10 - 50 millions dollars.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Arnel Capital Management -
Biossom Investment Management Beijing, Beijing, China
Blackfin Technology Boise, Idaho, United States
Breakaway Solutions Boston, Massachusetts, United States
C&D Co. -
Catholic Health Initiatives Colorado, Englewood, United States
Ceres Venture Fund Evanston, Illinois, United States
Chan Brothers Group Central, Central Region, Singapore
Fang Group Chaoyang, China, Liaoning
Four Rivers Group California, San Francisco, United States
HSBC Equipment Finance UK Ltd Birmingham, England, United Kingdom
Huaqiang Asset Management Group China, Guangdong, Shenzhen
Livag GmbH -
Meyer Equity New York, New York, United States
Prairie Capital Chicago, Illinois, United States
Prisma Energy International Houston, Texas, United States
Yeoman's Capital Austin, Texas, United States
ZJ Innopark (Zhangjiang Hi-Tech Park) China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Health Care
$3M28 Apr 2022 Singapore, Central Region, Singapore

Jio Health

Health Care
$20M12 Jan 2022 Vietnam, Ho Chi Minh City, Vietnam


$10M09 Dec 2021 Jakarta, Jakarta Raya, Indonesia


Electronic Health Record (EHR)
Health Care
Personal Health
06 Dec 2021 Singapore, Central, Singapore


Financial Services
$7M23 Nov 2021 Jakarta Pusat, Jakarta Raya, Indonesia


$5M19 Oct 2021 Noida, Uttar Pradesh, India


Artificial Intelligence
Health Care
$46M31 Aug 2021 Bengaluru, Karnataka, India

Hummingbird Bioscience

Health Care
$125M18 May 2021 Singapore, Central Region, Singapore


Artificial Intelligence
Health Care
$16M18 Jan 2021 Bengaluru, Karnataka, India
Hummingbird Bioscience Raises US$125M in Series C Financing

– Hummingbird Bioscience from Singapore develops precision therapies against hard-to-drug targets to improve treatment outcomes.
– Series C $125m round brings company valuation to more than $1b.
– The round was led by Novo Holdings with participation from new investors – Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Heritas Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: